FDA warns Hims that compounded semaglutide website claims are false or misleading and misbrand the drugs.
What happened
FDA reviewed https://www.hims.com in August 2025 and found the site offered compounded drug products, including semaglutide. FDA cited website claims such as “Same active ingredient as Ozempic and Wegovy” and “Clinically proven ingredients” as false or misleading because compounded drugs are not FDA-approved and the claims imply equivalence to approved products.
What FDA found
FDA says the website claim “Same active ingredient as Ozempic and Wegovy” is false or misleading because compounded semaglutide is not FDA-approved and the claim implies it is the same as approved products.
FDCA sections 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]FDA says the website claim “Clinically proven ingredients” is false or misleading for the same reason, misbranding the compounded semaglutide.
FDCA sections 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]FDA says introducing or delivering these misbranded products into interstate commerce is prohibited.
FDCA section 301(a) [21 U.S.C. § 331(a)]FDA says receiving misbranded drugs in interstate commerce and delivering them is also prohibited.
FDCA section 301(c) [21 U.S.C. § 331(c)]
What FDA wants
FDA tells Hims to take immediate action, including ceasing and desisting from using the cited language, and to respond in writing within 15 working days describing steps taken, documentation, and how it will prevent recurrence, or explain why it believes no violation exists.
Who should pay attention
- telehealth companies selling compounded semaglutide
- compounding pharmacies and their marketing partners
- brands or retailers advertising compounded drugs online
This is a summary. Read the original letter on fda.gov.